Gilead Sciences Inc
MIL:GILD

Watchlist Manager
Gilead Sciences Inc Logo
Gilead Sciences Inc
MIL:GILD
Watchlist
Price: 68.88 EUR 1.09% Market Closed
Market Cap: €85.9B

Operating Margin

39%
Current
Improving
by 0.7%
vs 3-y average of 38.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
39%
=
Operating Income
$11.3B
/
Revenue
$29.1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
39%
=
Operating Income
€11.3B
/
Revenue
$29.1B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
96.5B EUR
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
110.8B USD
Loading...
US
Biogen Inc
NASDAQ:BIIB
25B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...

Market Distribution

Higher than 95% of companies in the United States of America
Percentile
95th
Based on 14 112 companies
95th percentile
39%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Gilead Sciences Inc
Glance View

Gilead Sciences Inc., established in 1987, embarked on its mission with a resolute focus on innovative therapeutic advancements. Nestled in the biotech haven of Foster City, California, Gilead pioneered a path that would see it evolve into a global biopharmaceutical powerhouse. The company’s nucleus is its commitment to discovering, developing, and delivering therapies for diseases with unmet medical needs. Its product portfolio reflects this dedication, notably dominated by groundbreaking advancements in antiviral therapies, particularly for HIV/AIDS, hepatitis B, and hepatitis C. Over the years, its robust research and development engine, fueled by a continual reinvestment of earnings, propelled it to the forefront of tackling complex medical challenges. Its strategic acquisitions, like the pivotal purchase of Pharmasset in 2011, underpinned its ascent in the hepatitis C treatment arena, highlighting its aptitude for identifying and integrating synergistic growth opportunities. Financially, Gilead generates its revenue through the commercialization of its pharmaceutical portfolio. It thrives on a model where its novel therapies, once developed and approved, are sold to healthcare providers and systems. The landscape of antiviral treatments, primarily the revolutionary HIV regimen and hepatitis C cures like Harvoni and Sovaldi, serves as the backbone of its revenue stream. Meanwhile, Gilead's ventures into oncology and inflammatory diseases through strategic acquisitions and partnerships aim to diversify its portfolio beyond infectious diseases. The intricate process from innovation to distribution underscores Gilead’s proficient use of its clinical expertise and market acumen to address both expanding global health needs and shareholder demands, ensuring its enduring presence in the volatile seas of the biotech industry.

GILD Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
39%
=
Operating Income
$11.3B
/
Revenue
$29.1B
What is Gilead Sciences Inc's current Operating Margin?

The current Operating Margin for Gilead Sciences Inc is 39%, which is above its 3-year median of 38.3%.

How has Operating Margin changed over time?

Over the last 3 years, Gilead Sciences Inc’s Operating Margin has increased from 34.9% to 39%. During this period, it reached a low of 34.9% on Sep 30, 2022 and a high of 41.7% on Dec 31, 2022.

Back to Top